Search Result

Results for "

B-cell receptor

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Itk (1) 5-HT Receptor (1) ADC Antibody (1) Adenosine Receptor (1) Adrenergic Receptor (1) Akt (1) Apoptosis (5) BMX Kinase (1) Btk (9) CD19 (4) CD20 (2) Complement System (1) EBI2/GPR183 (1) Endogenous Metabolite (5) Fc Receptor (FcR) (1) HCV (1) Interleukin Related (1) IRAK (2) Isotope-Labeled Compounds (1) LAG-3 (1) Liposome (1) MALT1 (1) N-myristoyltransferase (1) p38 MAPK (1) PDGFR (1) Phosphatase (1) Phospholipase (2) PI3K (1) PROTACs (2) TNF Receptor (3) Toll-like Receptor (TLR) (3)
By Research Areas:	Cancer (21) Infection (2) Inflammation/Immunology (26) Metabolic Disease (1) Neurological Disease (1)
Oligonucleotides:	CpG ODNs (2)

Inhibitors & Agonists

Screening Libraries

Biochemical Assay Reagents

Inhibitory Antibodies

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Oligonucleotides

Targets Recommended: Programmed Cell Death 4 (PDCD4) Itk TOPK NAMPT ALCAM/CD166 GDNF Receptor VISTA BCL6 Tim3 BMI1

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-160142

UBX-382	Btk	Cancer
UBX-382 is an orally available proteolysis-targeting chimeras (PROTACs) that target BTK to inactivate B-cell receptor signaling. UBX-382 shows superior degradation activity for wild-type and mutant BTK proteins and shows anti-cancer activity in murine xenograft models of TMD-8 cells .

HY-NP006

Protein A SPA	Endogenous Metabolite	Inflammation/Immunology
Protein A (SPA) is an immunoglobulin (Ig) binding protein that exists on the surface of bacteria and can be freely secreted into the extracellular environment. Protein A blocks opsonization and phagocytosis and induces B-cell death in vitro by binding to the Fc region of antibodies and the Fab region of B-cell receptors. Protein A has the ability to inhibit opsonization and phagocytosis in vitro .

HY-129390

Orelabrutinib 3 Publications Verification ICP-022	Btk	Cancer
Orelabrutinib (ICP-022) is a potent, orally active, and irreversible Bruton's tyrosine kinase (BTK) inhibitor with potential antineoplastic activity. Orelabrutinib prevents both the activation of the B-cell antigen receptor (BCR) signaling pathway and BTK-mediated activation of downstream survival pathways, inhibiting the growth of malignant B-cells that overexpress BTK .

HY-111101

AZ1495	IRAK	Cancer
AZ1495, a weak base, is a potent orally active interleukin-1 receptor associated kinase 4 (IRAK4) inhibitor. AZ1495 has a favorable physicochemical and kinase selectivity for IRAK4 and IRAK1 with IC₅₀ values of 0.005 μM and 0.023 μM, respectively. AZ1495 has IRAK4 inhibition with a K_d value of 0.0007 μM. AZ1495 can be used for the research of diffuse large B-cell lymphoma (DLBCL) .

HY-P99483

Blontuvetmab AT 004; VT 007	CD20 Adenosine Receptor	Cancer
Blontuvetmab (AT 004) is a caninized CD20 monoclonal antibody and is also a potent, selective, highly potent antagonist of A2aR receptor. Blontuvetmab behaves as Nociceptin (HY-P0183)/Orphanin (HY-P0183) FQ receptor (NOP) agonists displaying weak NOP affinity. Blontuvetmab inhibits 5'-N-Ethylcarboxamidoadenosine (NECA)-mediated A2aR activation and significantly reverses the ability of adenosine to suppress CD8 T cell activation, increasing levels of cytokines such as IFN-γ. Blontuvetmab Blontuvetmab can be used for the research of Canine B-cell lymphoma .

HY-136268

AQX-435	Phosphatase Apoptosis	Inflammation/Immunology
AQX-435 is a potent SHIP1 phosphatase activator. AQX-435 reduces PI3K activation downstream of the B-cell receptor (BCR) and induces apoptosis of malignant B cells, and reduces lymphoma growth .

HY-147308

Zelenirstat 2 Publications Verification PCLX-001	N-myristoyltransferase	Cancer
Zelenirstat is an orally acitve, small-molecule, dual N-myristoyltransferase (NMT) inhibitor, with IC₅₀s of 5 nM (NMT1) and 8 nM (NMT2), respectively. Zelenirstat can induce cell apoptosis, has anti-cancer activity, inhibits early B cell receptor (BCR) signaling, and can be used to study malignant lymphoma .

HY-P99446

Atacicept TACI-Ig; TACI-Fc 5	TNF Receptor	Inflammation/Immunology
Atacicept (TACI-Ig) is a is a recombinant fusion protein containing the extracellular, ligand-binding portion of the TACI receptor and the Fc portion of human IgG. Atacicept inhibits B cell stimulation by binding to B lymphocyte stimulator and a proliferation-inducing ligand. Atacicept can be used in research of B-cell autoimmune disease .

HY-P99338

Tisagenlecleucel CTL019	CD19	Inflammation/Immunology Cancer
Tisagenlecleucel (CTL019) is an autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy. Tisagenlecleucel targets and eliminates CD19-expressing B cells. Tisagenlecleucel can be used for the research of refractory aggressive diffuse large B-cell lymphoma .

HY-P991514

MIL62	CD20	Cancer
MIL62 is a glycoengineered type II anti-CD20 monoclonal antibody with a nearly completely afucosylated N-glycans in Fc region. MIL62 shows enhanced affinity for the FcγRⅢa receptors and direct B-cell killing effects. MIL62 has antibody-dependent cell-mediated cytotoxicity (ADCC) activity. MIL62 can be used for the study of non-Hodgkin lymphoma (NHL) .

HY-153357

NRX-0492	PROTACs Btk	Cancer
NRX-0492 is an orally active PROTAC-class BTK degrader. NRX-0492 catalyzes BTK ubiquitination and proteasome degradation (DC₅₀ ≤ 0.2 nM, DC₉₀ ≤ 0.5 nM). NRX-0492 inhibits B cell receptor (BCR) mediated signaling, transcription programs, and chemokine secretion. NRX-0492 has antitumor effects against chronic lymphocytic leukemia.NRX-0492 consists of a target protein ligand (red part) BTK-IN-40 (HY-170324), an E3 ligase ligand (blue part) Thalidomide 5-fluoride (HY-W087383), and a PROTAC linker (black part) (3R)-3-Pyrrolidinemethanol (HY-60263).

HY-P99761

Obexelimab XmAb5871	CD19 Apoptosis	Inflammation/Immunology
Obexelimab (XmAb5871) is a humanized anti-CD19 antibody. Obexelimab works by inhibiting B cell receptor (BCR) mediated calcium influx and promoting the phosphorylation of Fc γ receptor IIb (FcγRIIb), which reduces B cell activation and function, leading to B cell apoptosis. Obexelimab can be used in research for rheumatoid arthritis and systemic lupus erythematosus .

HY-NP137

NP-PE (Phycoerythrin)	Complement System	Others
NP-PE (Phycoerythrin) is an immune complex. The formation and transport of NP-PE (Phycoerythrin) depends on the complement system, specifically through the complement receptors CR1 and CR2. These receptors are expressed on the surface of B cells and help B cells capture and transport immune complexes. NP-PE (Phycoerythrin) can be used to study the mechanisms by which B cells capture and transport immune complexes in lymph nodes .

HY-153085

CD19 CAR circRNA	CD19	Inflammation/Immunology Cancer
CD19 CAR circRNA will express CD19 car protein, and can be used in chimeric antigen receptor T cell immunotherapy (CAR-CD19). The CD19 car is a chimeric antigen receptor. Among them, CD19 is a CD molecule expressed by B cells (i.e. leukocyte differentiation antigen), an important membrane antigen involved in B cell proliferation, differentiation, activation and antibody production, and can also promote BCR signal transduction.

HY-147584

BTK-IN-14	Btk	Inflammation/Immunology Cancer
BTK-IN-14 is a potent inhibitor of BTK. BTK plays an important role in signaling mediated by B cell antigen receptor (BCR) and Fcγreceptor (FcγR) in B cells and myeloid cells, respectively. BTK-IN-14 has the potential for the research of related diseases, especially autoimmune diseases, inflammatory diseases or cancer (extracted from patent WO2022057894A1, compound 1) .

HY-147581

BTK-IN-11	Btk	Inflammation/Immunology Cancer
BTK-IN-11 is a potent inhibitor of BTK. BTK plays an important role in signaling mediated by B cell antigen receptor (BCR) and Fcγreceptor (FcγR) in B cells and myeloid cells, respectively. BTK-IN-11 has the potential for the research of related diseases, especially autoimmune diseases, inflammatory diseases or cancer (extracted from patent WO2022063101A1, compound Z2) .

HY-109010

Poseltinib 2 Publications Verification HM71224; LY3337641	Btk BMX Kinase Toll-like Receptor (TLR)	Metabolic Disease
Poseltinib (HM71224) is an orally active, selective, irreversible small molecule Bruton tyrosine kinase (BTK) inhibitor. With an IC₅₀ of 1.95 nM. Poseltinib effectively inhibits the signaling mediated by B cell receptors (BCR), Fc receptors (FcR), and Toll-like receptors (TLR). Poseltinib has anti-inflammatory activity and can be used in the research of rheumatoid arthritis .

HY-157562

DS68591889	Phospholipase Apoptosis	Cancer
DS68591889 is a selective and orally active phosphatidylserine synthase 1 (PTDSS1) inhibitor. DS68591889 has no inhibitory activity against PTDSS2. DS68591889 induces the phospholipid imbalance in a wide range of cancer cells. DS68591889 negatively regulates B cell receptor (BCR)-induced Ca ²⁺ signaling and subsequent apoptotic cell death. DS68591889 can be used for the cancer research, such as B cell lymphoma .

HY-113134

25-Hydroxycholesterol Maximum Cited Publications 23 Publications Verification 25-OHC	Endogenous Metabolite	Inflammation/Immunology
25-Hydroxycholesterol (25-OHC) is a metabolite of cholesterol that is produced and secreted by macrophages in response to Toll-like receptor (TLR) activation. 25-hydroxycholesterol is a potent (EC₅₀≈65 nM) and selective suppressor of IgA production by B cells.

HY-153234

CD19 car circRNA-LNP	CD19 Liposome	Inflammation/Immunology Cancer
CD19 car circRNA-LNP is a lipid nanoparticle (LNP) containing CD19 car circRNA, suitable for detection of RNA delivery, translation efficiency, cell viability, etc. CD19 car circRNA can be used in chimeric antigen receptor T cell immunotherapy (CAR-CD19). The CD19 car is a chimeric antigen receptor. Among them, CD19 is a CD molecule expressed by B cells (i.e. leukocyte differentiation antigen), an important membrane antigen involved in B cell proliferation, differentiation, activation and antibody production, and can also promote BCR signal transduction .

HY-158145

DS55980254	Phospholipase	Cancer
DS55980254 is the orally active inhibitor for phosphatidylserine synthase 1 (PTDSS1) that blocks the synthesis of intracellular phosphatidylserine. PTDSS1 deficiency affects the balance of cell membrane phospholipid components, and activates B cell receptor (BCR) signaling pathway .

HY-P990046

Tuparstobart Incagn-02385	LAG-3	Inflammation/Immunology
Tuparstobart (Incagn-02385) is an IgG1κ antibody targeting LAG-3. LAG-3 is an immune checkpoint receptor protein mainly expressed on activated T cells, NK cells, B cells and plasmacytoid dendritic cells .

HY-165484

AVP-13358	Interleukin Related	Inflammation/Immunology
AVP-13358 is an orally active IgE inhibitor that effectively suppresses immunoglobulin E (IgE)-mediated immune responses, with IC₅₀ values of 8 and 3 nM for IgE inhibition in vivo and in vitro in BALB/c mice, respectively. AVP-13358 acts directly on T cells, inhibiting the production and release of IL-4, IL-5, and IL-13. It also targets other markers critical for the development of allergic responses, including the B cell IgE receptor (CD23) in human monocytes and the CD23 and IL-4 receptors in mouse B cells. AVP-13358 can be used in research related to anti-allergic responses .

HY-160921

Capeserod SL65.0155 free base	5-HT Receptor	Neurological Disease
Capeserod (SL65.0155 free base) is an agonist for serotonin receptor (5-HT receptor), with a K_i of 0.6 nM for 5-HT₄ receptor. Capeserod enhances expression of phopshorilated cAMP-response element binding protein (p-CREB), vascular endothelium growth factor (VEGF), brain-derived neurotrophic factor (BDNF) and B cell lymphoma-2 (Bcl-2) proteins in hippocampus, and exhibits antidepressant-like efficacy in Wistar rats models .

HY-P99487

Briobacept BR 3FC	ADC Antibody	Inflammation/Immunology
Briobacept (BR 3FC) is a recombinant glucoprotein, consists of 2 molecules from the BLyS receptor (BR3)and a Fc domain of human IgG1. Briobacept selectively targets to BLyS (BAFF), induces B cells apoptosis. Briobacept can be used in studies of rheumatoid arthritis (RA) .

HY-113134R

25-Hydroxycholesterol (Standard)	Endogenous Metabolite	Inflammation/Immunology
25-Hydroxycholesterol (Standard) is the analytical standard of 25-Hydroxycholesterol. This product is intended for research and analytical applications. 25-Hydroxycholesterol (25-OHC) is a metabolite of cholesterol that is produced and secreted by macrophages in response to Toll-like receptor (TLR) activation. 25-hydroxycholesterol is a potent (EC50≈65 nM) and selective suppressor of IgA production by B cells.

HY-15771

Tirabrutinib 5+ Cited Publications ONO-4059; GS-4059	Btk Apoptosis	Inflammation/Immunology Cancer
Tirabrutinib (ONO-4059) is an orally active Bruton’s Tyrosine Kinase (BTK) inhibitor (can cross the blood-brain barrier (BBB)), with an IC₅₀ of 6.8 nM. Tirabrutinib irreversibly and covalently binds to BTK and inhibits aberrant B cell receptor signaling. Tirabrutinib can be used in studies of autoimmune diseases and hematological malignancies .

HY-15771A

Tirabrutinib hydrochloride 5+ Cited Publications ONO-4059 hydrochloride; GS-4059 hydrochloride	Btk Apoptosis	Inflammation/Immunology Cancer
Tirabrutinib (ONO-4059) hydrochloride is an orally active Bruton’s Tyrosine Kinase (BTK) inhibitor (can cross the blood-brain barrier (BBB)), with an IC₅₀ of 6.8 nM. Tirabrutinib hydrochloride irreversibly and covalently binds to BTK and inhibits aberrant B cell receptor signaling. Tirabrutinib hydrochloride can be used in studies of autoimmune diseases and hematological malignancies .

HY-114732

Procaterol	Adrenergic Receptor	Others
Procaterol is an oral selective β2 adrenergic receptor agonist. Procaterol inhibits eosinophil migration and the release of eosinophil chemotactic factor from BEAS-2B cells through a cyclic AMP-dependent mechanism. Procaterol has a large dose difference existing between the bronchodilator effect and the anabolic effect in rat, can be used for asthma research in athletes .

HY-118374

AM-9635	PI3K Akt	Inflammation/Immunology
AM-9635 is a selective PI3Kδ inhibitor with oral bioavailability, good in vitro and in vivo activity and pharmacodynamic properties. AM-9635 inhibits PI3Kδ-dependent B cell receptor-mediated AKT phosphorylation and suppresses the production of specific IgG and IgM antibodies in rats immunized with Aplysia leocyanin (KLH).

HY-113134S

25-Hydroxycholesterol-d6 25-OHC-d₆	Isotope-Labeled Compounds Endogenous Metabolite	Inflammation/Immunology
25-Hydroxycholesterol-d₆ (25-OHC-d₆) is the deuterium labeled 25-Hydroxycholesterol. 25-Hydroxycholesterol is a metabolite of cholesterol that is produced and secreted by macrophages in response to Toll-like receptor (TLR) activation. 25-hydroxycholesterol is a potent (EC₅₀≈65 nM) and selective suppressor of IgA production by B cells .

HY-143423A

(S)-MALT1-IN-5	MALT1	Inflammation/Immunology Cancer
(S)-MALT1-IN-5 is a potent inhibitor of MALT1 protease. (S)-MALT1-IN-5 inhibits the activity of MALT1 is expected to be able to correct the enhancement of MALT1 activity due to abnormality of T cell receptor signal or B cell receptor signal, and cancer or inflammatory disease caused by MALT1 activity is expected. (S)-MALT1-IN-5 has the potential for the research of MALT1-related diseases (extracted from patent WO2020111087A1, compound 1) .

HY-P99300

Ligelizumab 1 Publications Verification QGE 031; Anti-IGHE Recombinant Antibody	Fc Receptor (FcR)	Inflammation/Immunology
Ligelizumab (QGE 031) is a humanized high-affinity anti-immunoglobulin IgE monoclonal antibody. Ligelizumab selectively inhibits the binding of IgE to the high-affinity receptor FcεRI, while the inhibitory effect on the low-affinity receptor CD23 is weak. Ligelizumab can inhibit the activation of effector cells such as mast cells and Basophil, while reducing the production of IgE by B cells, and restoring the IFN-α production and regulatory T cell (Treg) induction function of plasmacytoid dendritic cells (pDC). Ligelizumab can be used in the study of allergic diseases (such as chronic spontaneous urticaria, allergic asthma) .

HY-150217A

CpG ODN 10101 sodium 1 Publications Verification ODN 10101 sodium	Toll-like Receptor (TLR)	Infection
CpG ODN 10101 sodium, a synthetic oligodeoxynucleotide (ODN), is a *toll-like receptor* 9 (TLR9)** agonist. CpG ODN 10101 sodium is a potent inducer of cytokine/chemokine expression ex vivo when used in combination with HH2(VQLRIRVAVIRA-NH2). CpG ODN 10101 sodium induces IFN- secretion from dendritic cells (DCs) and stimulates B-cells.CpG ODN 10101 sodium has antiviral and immunomodulatory properties that can influence chronic infection with HCV .

HY-113962

7α,25-Dihydroxycholesterol 2 Publications Verification 7α,25-OHC	EBI2/GPR183 Endogenous Metabolite	Inflammation/Immunology
7α, 25-dihydroxycholesterol (7α,25-OHC) is a potent and selective agonist and endogenous ligand of the orphan GPCR receptor EBI2 (GPR183). 7α, 25-dihydroxycholesterol is highly potent at activating EBI2 (EC₅₀=140 pM; K_d=450 pM). 7α, 25-dihydroxycholesterol can serve as a chemokine directing migration of B cells, T cells and dendritic cells .

HY-150217

CpG ODN 10101 1 Publications Verification ODN 10101	Toll-like Receptor (TLR) HCV	Infection Inflammation/Immunology
CpG ODN 10101, a synthetic oligodeoxynucleotide (ODN), is a *toll-like receptor* 9 (TLR9)** agonist. CpG ODN 10101 is a potent inducer of cytokine/chemokine expression ex vivo when used in combination with HH2(VQLRIRVAVIRA-NH2). CpG ODN 10101 induces IFN- secretion from dendritic cells (DCs) and stimulates B-cells.CpG ODN 10101 has antiviral and immunomodulatory properties that can influence chronic infection with HCV .

HY-P99315

Ruplizumab BG 9588; Anti-Human CD40L Recombinant Antibody; Hu5c8	TNF Receptor	Inflammation/Immunology
Ruplizumab (BG 9588) is a humanized anti-CD40L IgG1κ monoclonal antibody. By binding to CD40L, Ruplizumab blocks its interaction with the CD40 receptor, inhibits T-B cell costimulatory signals, and mediates the depletion of activated T cells via the Fc segment. Ruplizumab has immunosuppressive effects. Ruplizumab can be used in the study of systemic lupus erythematosus, organ transplant rejection, and autoimmune diseases. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .

HY-13644

Gusperimus 15-Deoxyspergualin	Others	Others
Gusperimus is a fully synthetic racemate that has a novel mechanism of action by binding to the intracellular heat shock protein hsp70 and interfering with intracellular signal transduction. This mechanism of action can enhance the effect of immunosuppressive therapy. Gusperimus can inhibit the differentiation of T cells into cytotoxic T cells, reduce the expression of IL-2 receptors on CD4 and CD8 cells, and inhibit IFN-γ-induced B cell maturation. In addition, when used with cyclosporine, tacrolimus or mycophenolate mofetil, Gusperimus can enhance the immunosuppressive effect and prevent allogeneic transplant rejection.

HY-150593

IRAK4-IN-16	IRAK	Cancer
IRAK4-IN-16 (compound 4) is a potent IRAK4 (interleukin-1 receptor associated kinase 4) inhibitor, with an IC₅₀ of 2.5 nM. IRAK4-IN-16 shows cytotoxicity activity against OCI-LY10, TMD8, Ramos and HT cells, with IC₅₀ values of 0.2, 0.2, 0.6, and 2.7 μM, respectively .

HY-P99459

Baminercept 1 Publications Verification BG 9924; TT-47	TNF Receptor	Inflammation/Immunology
Baminercept (BG 9924) is an *anti-lymphotoxin β receptor* (LTβR) IgG fusion protein (LTβR-Ig). Baminercept selectively binds to the LTβR ligand LTα/β heterotrimer and LIGHT*, block the LTβR signaling pathway, and inhibits the expression of chemokines such as CXCL13. Baminercept also regulates peripheral blood B cell* and T cell subsets, reduces the transcription of IFN-induced genes. Thereby, Baminercept inhibits the formation of high endothelial venules and reticular structures in lymphoid tissues, and affects immune cell migration. Baminercept can be used for the study of autoimmune diseases such as primary Sjogren's syndrome (pSS) and rheumatoid arthritis (RA) .

HY-170911

KIT/PDGFRA-IN-1	PDGFR	Cancer
KIT/PDGFRA-IN-1 (compound 19) is a *stem cell* growth factor receptor (KIT) and platelet-derived growth factor receptor alpha (PDGFRA) inhibitor. KIT/PDGFRA-IN-1 inhibits KIT-wt, KIT-D816H, KIT-T670I, PDGFRA-wt, PDGFRA-D842V, PDGFRA-T674I and PDGFRA-G680R with IC₅₀*s of 2.3, 12, 492, 0.8, 99.9, 42.3, and 4.3 μM, respectively. KIT/PDGFRA-IN-1 inhibits GIST-T1, T1-a-D842V and GIST-48B cells (PDGFR- and KIT-Mutant GIST cell* Lines) with GR₅₀s of 12, 8900, ≥10 000 nM, respectively .

HY-168963

PROTAC BTK Degrader-13	PROTACs Btk Itk p38 MAPK	Inflammation/Immunology Cancer
PROTAC BTK Degrader-13 (Compound 25) is the PROTAC degrader for BTK with a DC₅₀ of 0.27 μM. PROTAC BTK Degrader-13 inhibits the activity of BTK with an IC₅₀ of 0.44 μM, inhibits IL-2-induced T cell kinase (ITK) with an IC₅₀ of 2.16 μM. PROTAC BTK Degrader-13 inhibits p38 MAPK signaling pathway, block the activation of the BCR (B cell receptor) signaling pathway . (Pink: ligand for target protein BTK ligand 15 (HY-168965); Black: linker (HY-Y0524); Blue: ligand for E3 ligase cereblon (HY-103596))

Cat. No.	Product Name

HY-L156

Autoimmune Disease Compound Library	693 compounds
Autoimmune disease is a pathological disease characterized by inflammatory disorders targeting autoantigens. The routine treatment of autoimmune diseases suppresses general immune function to regulate uncontrolled inflammation. The current targeted immunotherapy suppresses the main pro-inflammatory signaling pathways by blocking inflammatory cytokines, cell surface molecules, and intracellular kinases. As key participants in innate immunity, macrophages and dendritic cells (DCs) are crucial for Ag presentation and pro-inflammatory cytokine production, such as TNF and IL-1 β、 IL-6, IL-23, B cell activating factor (BAFF), and the proliferation-inducing ligand (APRIL, also known as TNFSF13A). MCE designs a unique collection of 693 autoimmune disease-related compounds, covering multiple targets and subtypes, such as TNF Receptor, IFNAR, JAK, Btk, TLR, IL-6, IL-17, IL-23, etc. It is a useful tool for screening autoimmune disease drugs.

Autoimmune Disease Compound Library

693 compounds

Autoimmune disease is a pathological disease characterized by inflammatory disorders targeting autoantigens. The routine treatment of autoimmune diseases suppresses general immune function to regulate uncontrolled inflammation. The current targeted immunotherapy suppresses the main pro-inflammatory signaling pathways by blocking inflammatory cytokines, cell surface molecules, and intracellular kinases. As key participants in innate immunity, macrophages and dendritic cells (DCs) are crucial for Ag presentation and pro-inflammatory cytokine production, such as TNF and IL-1 β、 IL-6, IL-23, B cell activating factor (BAFF), and the proliferation-inducing ligand (APRIL, also known as TNFSF13A).

MCE designs a unique collection of 693 autoimmune disease-related compounds, covering multiple targets and subtypes, such as TNF Receptor, IFNAR, JAK, Btk, TLR, IL-6, IL-17, IL-23, etc. It is a useful tool for screening autoimmune disease drugs.

Cat. No.	Product Name	Type

HY-NP006

Protein A SPA	Native Proteins
Protein A (SPA) is an immunoglobulin (Ig) binding protein that exists on the surface of bacteria and can be freely secreted into the extracellular environment. Protein A blocks opsonization and phagocytosis and induces B-cell death in vitro by binding to the Fc region of antibodies and the Fab region of B-cell receptors. Protein A has the ability to inhibit opsonization and phagocytosis in vitro .

Protein A

SPA

Native Proteins

Protein A (SPA) is an immunoglobulin (Ig) binding protein that exists on the surface of bacteria and can be freely secreted into the extracellular environment. Protein A blocks opsonization and phagocytosis and induces B-cell death in vitro by binding to the Fc region of antibodies and the Fab region of B-cell receptors. Protein A has the ability to inhibit opsonization and phagocytosis in vitro .

HY-NP137

NP-PE (Phycoerythrin)

Native Proteins

NP-PE (Phycoerythrin) is an immune complex. The formation and transport of NP-PE (Phycoerythrin) depends on the complement system, specifically through the complement receptors CR1 and CR2. These receptors are expressed on the surface of B cells and help B cells capture and transport immune complexes. NP-PE (Phycoerythrin) can be used to study the mechanisms by which B cells capture and transport immune complexes in lymph nodes .

HY-153234

CD19 car circRNA-LNP

Drug Delivery

CD19 car circRNA-LNP is a lipid nanoparticle (LNP) containing CD19 car circRNA, suitable for detection of RNA delivery, translation efficiency, cell viability, etc. CD19 car circRNA can be used in chimeric antigen receptor T cell immunotherapy (CAR-CD19). The CD19 car is a chimeric antigen receptor. Among them, CD19 is a CD molecule expressed by B cells (i.e. leukocyte differentiation antigen), an important membrane antigen involved in B cell proliferation, differentiation, activation and antibody production, and can also promote BCR signal transduction .

Cat. No.	Product Name	Target	Research Area

HY-P99483

Blontuvetmab AT 004; VT 007	CD20 Adenosine Receptor	Cancer
Blontuvetmab (AT 004) is a caninized CD20 monoclonal antibody and is also a potent, selective, highly potent antagonist of A2aR receptor. Blontuvetmab behaves as Nociceptin (HY-P0183)/Orphanin (HY-P0183) FQ receptor (NOP) agonists displaying weak NOP affinity. Blontuvetmab inhibits 5'-N-Ethylcarboxamidoadenosine (NECA)-mediated A2aR activation and significantly reverses the ability of adenosine to suppress CD8 T cell activation, increasing levels of cytokines such as IFN-γ. Blontuvetmab Blontuvetmab can be used for the research of Canine B-cell lymphoma .

HY-P99446

Atacicept TACI-Ig; TACI-Fc 5	TNF Receptor	Inflammation/Immunology
Atacicept (TACI-Ig) is a is a recombinant fusion protein containing the extracellular, ligand-binding portion of the TACI receptor and the Fc portion of human IgG. Atacicept inhibits B cell stimulation by binding to B lymphocyte stimulator and a proliferation-inducing ligand. Atacicept can be used in research of B-cell autoimmune disease .

HY-P99400

Samalizumab 1 Publications Verification ALXN 6000	Inhibitory Antibodies	Cancer
Samalizumab (ALXN 6000) is a humanized monoclonal antibody that specifically binds to CD200 and blocks its ligation to the CD200 receptor (CD200R). Samalizumab can be used for multiple myeloma and B-cell chronic lymphocytic leukemia research .

HY-P99761

Obexelimab XmAb5871	CD19 Apoptosis	Inflammation/Immunology
Obexelimab (XmAb5871) is a humanized anti-CD19 antibody. Obexelimab works by inhibiting B cell receptor (BCR) mediated calcium influx and promoting the phosphorylation of Fc γ receptor IIb (FcγRIIb), which reduces B cell activation and function, leading to B cell apoptosis. Obexelimab can be used in research for rheumatoid arthritis and systemic lupus erythematosus .

HY-P99487

Briobacept BR 3FC	ADC Antibody	Inflammation/Immunology
Briobacept (BR 3FC) is a recombinant glucoprotein, consists of 2 molecules from the BLyS receptor (BR3)and a Fc domain of human IgG1. Briobacept selectively targets to BLyS (BAFF), induces B cells apoptosis. Briobacept can be used in studies of rheumatoid arthritis (RA) .

HY-P99300

Ligelizumab 1 Publications Verification QGE 031; Anti-IGHE Recombinant Antibody	Fc Receptor (FcR)	Inflammation/Immunology
Ligelizumab (QGE 031) is a humanized high-affinity anti-immunoglobulin IgE monoclonal antibody. Ligelizumab selectively inhibits the binding of IgE to the high-affinity receptor FcεRI, while the inhibitory effect on the low-affinity receptor CD23 is weak. Ligelizumab can inhibit the activation of effector cells such as mast cells and Basophil, while reducing the production of IgE by B cells, and restoring the IFN-α production and regulatory T cell (Treg) induction function of plasmacytoid dendritic cells (pDC). Ligelizumab can be used in the study of allergic diseases (such as chronic spontaneous urticaria, allergic asthma) .

HY-P990680

Anti-Mouse CD40 Antibody (FGK4.5/FGK45)	Inhibitory Antibodies	Inflammation/Immunology
Anti-Mouse CD40 Antibody (FGK4.5/FGK45) is a rat-derived IgG2a monoclonal antibody targeting mouse CD40. CD40 is a type I transmembrane glycoprotein that belongs to the tumor necrosis factor receptor (TNFR) superfamily. CD40 can act as a co-stimulatory molecule to activate B cells, dendritic cells, monocytes, and other APCs, promoting anti-tumor T cell responses.

HY-P99338

Tisagenlecleucel CTL019	CD19	Inflammation/Immunology Cancer
Tisagenlecleucel (CTL019) is an autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy. Tisagenlecleucel targets and eliminates CD19-expressing B cells. Tisagenlecleucel can be used for the research of refractory aggressive diffuse large B-cell lymphoma .

HY-P991514

MIL62	CD20	Cancer
MIL62 is a glycoengineered type II anti-CD20 monoclonal antibody with a nearly completely afucosylated N-glycans in Fc region. MIL62 shows enhanced affinity for the FcγRⅢa receptors and direct B-cell killing effects. MIL62 has antibody-dependent cell-mediated cytotoxicity (ADCC) activity. MIL62 can be used for the study of non-Hodgkin lymphoma (NHL) .

HY-P990046

Tuparstobart Incagn-02385	LAG-3	Inflammation/Immunology
Tuparstobart (Incagn-02385) is an IgG1κ antibody targeting LAG-3. LAG-3 is an immune checkpoint receptor protein mainly expressed on activated T cells, NK cells, B cells and plasmacytoid dendritic cells .

HY-P99315

Ruplizumab BG 9588; Anti-Human CD40L Recombinant Antibody; Hu5c8	TNF Receptor	Inflammation/Immunology
Ruplizumab (BG 9588) is a humanized anti-CD40L IgG1κ monoclonal antibody. By binding to CD40L, Ruplizumab blocks its interaction with the CD40 receptor, inhibits T-B cell costimulatory signals, and mediates the depletion of activated T cells via the Fc segment. Ruplizumab has immunosuppressive effects. Ruplizumab can be used in the study of systemic lupus erythematosus, organ transplant rejection, and autoimmune diseases. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .

HY-P99459

Baminercept 1 Publications Verification BG 9924; TT-47	TNF Receptor	Inflammation/Immunology
Baminercept (BG 9924) is an *anti-lymphotoxin β receptor* (LTβR) IgG fusion protein (LTβR-Ig). Baminercept selectively binds to the LTβR ligand LTα/β heterotrimer and LIGHT*, block the LTβR signaling pathway, and inhibits the expression of chemokines such as CXCL13. Baminercept also regulates peripheral blood B cell* and T cell subsets, reduces the transcription of IFN-induced genes. Thereby, Baminercept inhibits the formation of high endothelial venules and reticular structures in lymphoid tissues, and affects immune cell migration. Baminercept can be used for the study of autoimmune diseases such as primary Sjogren's syndrome (pSS) and rheumatoid arthritis (RA) .

Species:	Human (21) Rhesus Macaque (4) Mouse (6) Rat (5) Cynomolgus (4) Canine (1)
Tag:	His (25) Avi (4) Fc (17) Flag (2)
Source:	HEK293 (41)

Cat. No.	Compare	Product Name	Species	Source

HY-P70560

	Siglec-2/CD22 Protein, Human (668a.a, HEK293, Fc) Siglec-2; CD22; B-cell receptor CD22	Human	HEK293
	The Siglec-2/CD22 protein mediates B cell interactions and may direct B cell localization within lymphoid tissues. It recognizes sialylated glycoproteins, especially α-2,6-linked sialic acid, and participates in cis-interactions at the cell surface. Siglec-2/CD22 Protein, Human (668a.a, HEK293, Fc) is the recombinant human-derived Siglec-2/CD22 protein, expressed by HEK293 , with C-hFc labeled tag.

HY-P72019

	Siglec-2/CD22 Protein, Human (HEK293, His) B-cell receptor CD22; BL-CAM; Siglec-2; CD22; SIGLEC2	Human	HEK293
	The Siglec-2/CD22 protein mediates B cell interactions and may direct B cell localization within lymphoid tissues. It recognizes sialylated glycoproteins, especially α-2,6-linked sialic acid, and participates in cis-interactions at the cell surface. Siglec-2/CD22 Protein, Human (HEK293, His) is the recombinant human-derived Siglec-2/CD22 protein, expressed by HEK293 , with C-6*His labeled tag.

HY-P72474A

	Siglec-2/CD22 Protein, Mouse (HEK293, His) B-cell receptor CD22; BL-CAM; Siglec-2; CD22; Lyb-8	Mouse	HEK293
	Siglec-2/CD22 is a B cell surface receptor that mediates B cell interactions and is involved in B cell localization within lymphoid tissues. It selectively binds α-2,6-linked sialic acids, including CD45, and its sialic acid recognition site may be regulated by cis interactions. Siglec-2/CD22 Protein, Mouse (HEK293, His) is the recombinant mouse-derived Siglec-2/CD22 protein, expressed by HEK293 , with C-6*His labeled tag.

HY-P72707

	CD79B Protein, Mouse (HEK293, Fc) B-cell antigen receptor complex-associated protein beta chain; CD79b; B29; IGB	Mouse	HEK293
	CD79B protein, together with CD79A, initiates the B-cell antigen receptor complex (BCR) signaling cascade, which is critical for complex internalization and transport to late endosomes, promoting antigen presentation. CD79B enhances CD79A phosphorylation, possibly recruiting kinases or protective proteins. CD79B Protein, Mouse (HEK293, Fc) is the recombinant mouse-derived CD79B protein, expressed by HEK293 , with C-hFc labeled tag.

HY-P704490

	CD79 Protein, Human (HEK293, mFc-Flag, mFc-His) CD79A&CD79B; B-cell antigen receptor complex-associated protein alpha chain; B-cell antigen receptor complex-associated protein beta chain	Human	HEK293

HY-P704302

	FITC-Labeled Siglec-2/CD22 Protein, Human (HEK293, His) Siglec-2; CD22; B-cell receptor CD22	Human	HEK293
	The Siglec-2/CD22 protein mediates B cell interactions and may direct B cell localization within lymphoid tissues. It recognizes sialylated glycoproteins, especially α-2,6-linked sialic acid, and participates in cis-interactions at the cell surface. FITC-Labeled Siglec-2/CD22 Protein, Human (HEK293, His) is the recombinant human-derived FITC-Labeled Siglec-2/CD22 protein, expressed by HEK293, with C-His labeled tag.

HY-P78641

	Siglec-2/CD22 Protein, Canine (HEK293, His) B-cell receptor CD22; BL-CAM; Siglec-2; CD22; SIGLEC2	Canine	HEK293
	The Siglec-2/CD22 protein mediates B cell interactions and may direct B cell localization within lymphoid tissues. It recognizes sialylated glycoproteins, especially α-2,6-linked sialic acid, and participates in cis-interactions at the cell surface. Siglec-2/CD22 Protein, Canine (HEK293, His) is the recombinant canine-derived Siglec-2/CD22 protein, expressed by HEK293 , with C-His labeled tag. The total length of Siglec-2/CD22 Protein, Canine (HEK293, His) is 718 a.a., with molecular weight of 115-130 kDa.

HY-P704294

	Siglec-2/CD22 Protein, Human (668a.a, HEK293, Llama Fc) Siglec-2; CD22; B-cell receptor CD22	Human	HEK293
	The Siglec-2/CD22 protein mediates B cell interactions and may direct B cell localization within lymphoid tissues. It recognizes sialylated glycoproteins, especially α-2,6-linked sialic acid, and participates in cis-interactions at the cell surface. Siglec-2/CD22 Protein, Human (668a.a, HEK293, Llama Fc) is the recombinant human-derived Siglec-2/CD22 protein, expressed by HEK293, with C-Llama Fc labeled tag.

HY-P72709

	CD79A Protein, Human (HEK293, His) B-cell antigen receptor complex-associated protein alpha chain; CD79a; IGA; MB1	Human	HEK293
	The CD79A protein is critical for initiating the B cell antigen receptor complex (BCR) signaling cascade upon antigen binding. It promotes internalization, transport to late endosomes, and antigen presentation of BCR complexes. CD79A Protein, Human (HEK293, His) is the recombinant human-derived CD79A protein, expressed by HEK293 , with C-6*His labeled tag.

HY-P75383

	CD79A Protein, Mouse (HEK293, Fc) B-cell antigen receptor complex-associated protein alpha chain; CD79a; IGA; MB1	Mouse	HEK293
	CD79A cooperates with CD79B to initiate the B cell antigen receptor complex (BCR) signaling cascade upon antigen binding. This results in complex internalization, transport and antigen presentation. CD79A Protein, Mouse (HEK293, Fc) is the recombinant mouse-derived CD79A protein, expressed by HEK293 , with C-hFc labeled tag.

HY-P75626

	CD22 Protein, Rhesus Macaque (HEK293, Fc) B-cell receptor CD22; BL-CAM; CD22; T-cell surface antigen Leu-14	Rhesus Macaque	HEK293
	The Siglec-2/CD22 protein mediates B cell interactions and may direct B cell localization within lymphoid tissues.It recognizes sialylated glycoproteins, especially α-2,6-linked sialic acid, and participates in cis-interactions at the cell surface.CD22 Protein, Rhesus Macaque (HEK293, Fc) is the recombinant Rhesus Macaque-derived CD22 protein, expressed by HEK293 , with C-hFc labeled tag.

HY-P75627

	CD22 Protein, Rhesus Macaque (HEK293, His) B-cell receptor CD22; BL-CAM; CD22; T-cell surface antigen Leu-14	Rhesus Macaque	HEK293
	The Siglec-2/CD22 protein mediates B cell interactions and may direct B cell localization within lymphoid tissues.It recognizes sialylated glycoproteins, especially α-2,6-linked sialic acid, and participates in cis-interactions at the cell surface.CD22 Protein, Rhesus Macaque (HEK293, His) is the recombinant Rhesus Macaque-derived CD22 protein, expressed by HEK293 , with C-His labeled tag.

HY-P75658

	CD79B Protein, Rat (HEK293, Fc) B-cell antigen receptor complex-associated protein beta chain; CD79b; B29; IGB	Rat	HEK293
	CD79B Protein, also known as B29 or Igβ, is an essential component of the B cell receptor along with immunoglobulin and mb1 (Igα, CD79a) and is absolutely required for B cell development. Rat CD79B protein comprises 228 amino acids, and its amino acid sequence is 85 and 69% identical with the mouse and human counterparts, respectively. The B-cell antigen receptor (BCR) signaling component Igβ (CD79B) and the co-receptor CD19 act as an alternative B-cell signaling module that promotes the survival of B lymphoma and normal B cells via integrated ITAM/PI3K signaling. The loss of CD79B causes a block in N-glycan maturation and accumulation of immature proteins. CD79B Protein, Rat (HEK293, Fc) is the recombinant rat-derived CD79B protein, expressed by HEK293 , with C-hFc labeled tag.

HY-P75659

	CD79B Protein, Rat (HEK293, His) B-cell antigen receptor complex-associated protein beta chain; CD79b; B30; IGB	Rat	HEK293
	CD79B Protein, also known as B29 or Igβ, is an essential component of the B cell receptor along with immunoglobulin and mb1 (Igα, CD79a) and is absolutely required for B cell development. Rat CD79B protein comprises 228 amino acids, and its amino acid sequence is 85 and 69% identical with the mouse and human counterparts, respectively. The B-cell antigen receptor (BCR) signaling component Igβ (CD79B) and the co-receptor CD19 act as an alternative B-cell signaling module that promotes the survival of B lymphoma and normal B cells via integrated ITAM/PI3K signaling. The loss of CD79B causes a block in N-glycan maturation and accumulation of immature proteins. CD79B Protein, Rat (HEK293, His) is the recombinant rat-derived CD79B protein, expressed by HEK293 , with C-His labeled tag.

HY-P77537

	Siglec-2/CD22 Protein, Human (Biotinylated, HEK293, His) B-cell receptor CD22; BL-CAM; Siglec-2; CD22; SIGLEC2	Human	HEK293
	The Siglec-2/CD22 protein mediates B cell interactions and may direct B cell localization within lymphoid tissues. It recognizes sialylated glycoproteins, especially α-2,6-linked sialic acid, and participates in cis-interactions at the cell surface. Siglec-2/CD22 Protein, Human (Biotinylated, HEK293, His) is the recombinant human-derived Siglec-2/CD22 protein, expressed by HEK293 , with C-His labeled tag.

HY-P72708

	CD79B Protein, Rhesus Macaque (HEK293, His) B-cell antigen receptor complex-associated protein beta chain; CD79b; B29; IGB	Rhesus Macaque	HEK293
	CD79B protein binds to CD79A and initiates the B cell antigen receptor complex (BCR) signaling cascade. This results in complex internalization, transport to late endosomes and antigen presentation. CD79B Protein, Rhesus Macaque (HEK293, His) is the recombinant Rhesus Macaque-derived CD79B protein, expressed by HEK293 , with C-6*His labeled tag.

HY-P75385

	CD79 Protein, Mouse (HEK293, His) B-cell antigen receptor complex-associated protein; CD79a; IGA; MB1; CD79b; IGB	Mouse	HEK293
	CD79A cooperates with CD79B to initiate the B cell antigen receptor complex (BCR) signaling cascade upon antigen binding. This results in complex internalization, transport and antigen presentation. CD79 Protein, Mouse (HEK293, His) is a recombinant protein dimer complex containing mouse-derived CD79 protein, expressed by HEK293 , with C-His labeled tag. CD79 Protein, Mouse (HEK293, His), has molecular weight of 23-43 kDa, respectively.

HY-P75430

	Siglec-2/CD22 Protein, Rat (HEK293, His) B-cell receptor CD22; BL-CAM; CD22; T-cell surface antigen Leu-14	Rat	HEK293
	The Siglec-2/CD22 protein mediates B cell interactions and may direct B cell localization within lymphoid tissues. It recognizes sialylated glycoproteins, especially α-2,6-linked sialic acid, and participates in cis-interactions at the cell surface. Siglec-2/CD22 Protein, Rat (HEK293, His) is the recombinant rat-derived Siglec-2/CD22 protein, expressed by HEK293 , with C-His labeled tag.

HY-P75431

	Siglec-2/CD22 Protein, Rat (HEK293, Fc) B-cell receptor CD22; BL-CAM; CD22; T-cell surface antigen Leu-14	Rat	HEK293
	The Siglec-2/CD22 protein mediates B cell interactions and may direct B cell localization within lymphoid tissues. It recognizes sialylated glycoproteins, especially α-2,6-linked sialic acid, and participates in cis-interactions at the cell surface. Siglec-2/CD22 Protein, Rat (HEK293, Fc) is the recombinant rat-derived Siglec-2/CD22 protein, expressed by HEK293 , with C-hFc labeled tag.

HY-P75386A

	CD79 Protein, Human (HEK293, His) B-cell antigen receptor complex-associated protein; CD79a; IGA; MB1; CD79b; IGB	Human	HEK293
	The CD79A protein is critical for initiating the B cell antigen receptor complex (BCR) signaling cascade upon antigen binding. It promotes internalization, transport to late endosomes, and antigen presentation of BCR complexes. CD79 Protein, Human (HEK293, His) is the recombinant human-derived CD79, expressed by HEK293 , with C-6*His labeled tag. ,

HY-P704142

	CD79 Protein, Cynomolgus (HEK293, His) B-cell antigen receptor complex-associated protein; CD79a; IGA; MB1; CD79b; IGB	Cynomolgus	HEK293
	CD79 Protein, Cynomolgus (HEK293, His) is the recombinant cynomolgus-derived CD79 protein, expressed by HEK293, with C-His tag.

HY-P72474

	Siglec-2/CD22 Protein, Mouse (AAA02562.1, HEK293, His) B-cell receptor CD22; BL-CAM; Siglec-2; CD22; Lyb-8	Mouse	HEK293
	Siglec-2/CD22 Protein mediates B-cell B-cell interaction and may be involved in the localization of B-cells in lymphoid tissues. Siglec-2/CD22 Protein, Mouse (AAA02562.1, HEK293, His) is the recombinant mouse-derived Siglec-2/CD22 protein, expressed by HEK293 , with C-6*His labeled tag.

HY-P73646

	Siglec-2/CD22 Protein, Mouse (690a.a, HEK293, Fc) B-cell receptor CD22; BL-CAM; Siglec-2; CD22; SIGLEC2	Mouse	HEK293
	Siglec-2/CD22 Protein, Mouse (690a.a, HEK293, Fc) is a Siglec of ~140 kDa with seven Ig-like domains and is expressed in a B-cell lineage-specific fashion, starting at the pre-B cell stage. CD22 is associated with membrane-bound IgM on the surface of B cells. Siglec-2 (CD22) specifically recognizes 伪2.6 sialic acid-containing glycans. Siglec-2 negatively regulates B cell antigen receptor (BCR) signaling by recruitment and activation of SH2-containing phosphatase 1 (SHP-1), which counteracts the phospharylation-mediated activation of signaling molecules by dephosphorylation, and reduces Ca²⁺ signaling by regulating the activity of the Ca²⁺ pump PMCA. Siglec-2/CD22 Protein, Mouse (690a.a, HEK293, Fc) is the recombinant mouse-derived Siglec-2/CD22 protein, expressed by HEK293 , with C-hFc labeled tag.

HY-P73648

	Siglec-2/CD22 Protein, Human (512a.a, HEK293, His) B-cell receptor CD22; BL-CAM; Siglec-2; CD22; SIGLEC2	Human	HEK293
	The Siglec-2/CD22 protein mediates B cell interactions and may direct B cell localization within lymphoid tissues. It recognizes sialylated glycoproteins, especially α-2,6-linked sialic acid, and participates in cis-interactions at the cell surface. Siglec-2/CD22 Protein, Human (512a.a, HEK293, His) is the recombinant human-derived Siglec-2/CD22 protein, expressed by HEK293 , with C-His labeled tag.

HY-P75386

	CD79 Protein, Human (HEK293, Flag-His) B-cell antigen receptor complex-associated protein; CD79a; IGA; MB1; CD79b; IGB	Human	HEK293
	The CD79A protein is critical for initiating the B cell antigen receptor complex (BCR) signaling cascade upon antigen binding. It promotes internalization, transport to late endosomes, and antigen presentation of BCR complexes. CD79 Protein, Human (HEK293, Flag-His) is a recombinant protein dimer complex containing human-derived CD79 protein, expressed by HEK293 , with C-His, C-Flag labeled tag. CD79 Protein, Human (HEK293, Flag-His), has molecular weight of ~37.5 kDa.

HY-P78626

	Siglec-2/CD22 Protein, Rat (669a.a, HEK293, His) B-cell receptor CD22; BL-CAM; Siglec-2; CD22; SIGLEC2	Rat	HEK293
	The Siglec-2/CD22 protein mediates B cell interactions and may direct B cell localization within lymphoid tissues. It recognizes sialylated glycoproteins, especially α-2,6-linked sialic acid, and participates in cis-interactions at the cell surface. Siglec-2/CD22 Protein, Rat (669a.a, HEK293, His) is the recombinant rat-derived Siglec-2/CD22 protein, expressed by HEK293 , with C-His labeled tag. The total length of Siglec-2/CD22 Protein, Rat (669a.a, HEK293, His) is 669 a.a., with molecular weight of 100-150 kDa.

HY-P77539

	Siglec-2/CD22 Protein, Human (Biotinylated, 512a.a, HEK293, His) B-cell receptor CD22; BL-CAM; Siglec-2; CD22; SIGLEC2	Human	HEK293
	The Siglec-2/CD22 protein mediates B cell interactions and may direct B cell localization within lymphoid tissues. It recognizes sialylated glycoproteins, especially α-2,6-linked sialic acid, and participates in cis-interactions at the cell surface. Siglec-2/CD22 Protein, Human (Biotinylated, 512a.a, HEK293, His) is the recombinant human-derived Siglec-2/CD22 protein, expressed by HEK293 , with C-His labeled tag.

HY-P70778

	BCMA/TNFRSF17 Protein, Cynomolgus (HEK293, His) Tumor necrosis factor receptor superfamily member 17; B-cell maturation protein; CD269; Tnfrsf17; Bcm; Bcma	Cynomolgus	HEK293
	B Cell Maturation Antigen (BCMA) also referred to as TNFRSF17 or CD269, is a transmembrane glycoprotein member of the tumor necrosis factor receptor (TNFR) superfamily. BCMA is used as a biomarker for Multiple myeloma (MM). BCMA mainly plays an important role in B cells for their proliferation, survival and also differentiates them into plasma cells. BCMA/TNFRSF17 Protein, Cynomolgus (HEK293, His) is a recombinant protein with a C-Terminal His label, It consists of 53 amino acids (M1-A53) and is produced in HEK293 cells.

HY-P70827

	BCMA/TNFRSF17 Protein, Human (HEK293, mFc) Tumor necrosis factor receptor superfamily member 17; B-cell maturation protein; CD269; Tnfrsf17; Bcm; Bcma	Human	HEK293
	B Cell Maturation Antigen (BCMA) also referred to as TNFRSF17 or CD269, is a transmembrane glycoprotein member of the tumor necrosis factor receptor (TNFR) superfamily. BCMA is used as a biomarker for Multiple myeloma (MM). BCMA mainly plays an important role in B cells for their proliferation, survival and also differentiates them into plasma cells. BCMA/TNFRSF17 Protein, Human (HEK293, mFc) is a recombinant protein with a C-Terminal Fc label, It consists of 54 amino acids (M1-A54) and is produced in HEK293 cells.

HY-P72342

	BCMA/TNFRSF17 Protein, Human (Biotinylated, HEK293, Fc-Avi) Tumor necrosis factor receptor superfamily member 17; TNFRSF17; B-cell maturation protein; CD269	Human	HEK293
	B Cell Maturation Antigen (BCMA) also referred to as TNFRSF17 or CD269, is a transmembrane glycoprotein member of the tumor necrosis factor receptor (TNFR) superfamily. BCMA is used as a biomarker for Multiple myeloma (MM). BCMA mainly plays an important role in B cells for their proliferation, survival and also differentiates them into plasma cells. BCMA/TNFRSF17 Protein, Human (Biotinylated, HEK293, Fc-Avi) is a biotinylated recombinant protein with a C-Terminal Avi label and a C-Terminal Fc label, It consists of 54 amino acids (M1-A54) and is produced in HEK293 cells.

HY-P7654

	BCMA/TNFRSF17 Protein, Human (HEK293, Fc) rHuCMA/TNFRSF17, C-Fc; Tumor necrosis factor receptor superfamily member 17; TNFRSF17; B-cell maturation protein	Human	HEK293
	B Cell Maturation Antigen (BCMA) also referred to as TNFRSF17 or CD269, is a transmembrane glycoprotein member of the tumor necrosis factor receptor (TNFR) superfamily. BCMA is used as a biomarker for Multiple myeloma (MM). BCMA mainly plays an important role in B cells for their proliferation, survival and also differentiates them into plasma cells. BCMA/TNFRSF17 Protein, Human (HEK293, Fc) is a recombinant protein with a C-Terminal Fc label, It consists of 54 amino acids (M1-A54) and is produced in HEK293 cells.

HY-P700895

	Siglec-2/CD22 Protein, Rhesus macaque (HEK293, His) CD22 molecule; CD22; Siglec-2; B-cell receptor CD22; BL-CAM; SIGLEC2; SIGLEC2FLJ22814	Rhesus Macaque	HEK293
	The Siglec-2/CD22 protein mediates B cell interactions and may direct B cell localization within lymphoid tissues. It recognizes sialylated glycoproteins, especially α-2,6-linked sialic acid, and participates in cis-interactions at the cell surface. Siglec-2/CD22 Protein, Rhesus macaque (HEK293, His) is the recombinant Rhesus Macaque-derived Siglec-2/CD22 protein, expressed by HEK293 , with C-His labeled tag.

HY-P70541

	CD79B Protein, Human (HEK293, His) B-cell Antigen receptor Complex-Associated Protein Beta Chain; B-cell-Specific Glycoprotein B29; Ig-Beta; Immunoglobulin-Associated B29 Protein; CD79b; CD79B; B29; IGB	Human	HEK293
	CD79B protein binds to CD79A and initiates the B cell antigen receptor complex (BCR) signaling cascade. This results in complex internalization, transport to late endosomes and antigen presentation. CD79B Protein, Human (HEK293, His) is the recombinant human-derived CD79B protein, expressed by HEK293 , with C-6*His labeled tag.

HY-P704492

	CD79B Protein, Human (HEK293, hFc) B-cell Antigen receptor Complex-Associated Protein Beta Chain; B-cell-Specific Glycoprotein B29; Ig-Beta; Immunoglobulin-Associated B29 Protein; CD79b; CD79B; B29; IGB	Human	HEK293
	CD79B protein binds to CD79A and initiates the B cell antigen receptor complex (BCR) signaling cascade. This results in complex internalization, transport to late endosomes and antigen presentation. CD79B Protein, Human (HEK293, hFc) is the recombinant human-derived CD79B protein, expressed by HEK293, with C-hFc labeled tag.

HY-P70768

	CD79B Protein, Human (Biotinylated, HEK293, His-Avi) B-cell Antigen receptor Complex-Associated Protein Beta Chain; B-cell-Specific Glycoprotein B29; Ig-Beta; Immunoglobulin-Associated B29 Protein; CD79b; CD79B; B29; IGB	Human	HEK293
	CD79B protein binds to CD79A and initiates the B cell antigen receptor complex (BCR) signaling cascade. This results in complex internalization, transport to late endosomes and antigen presentation. CD79B Protein, Human (Biotinylated, HEK293, His-Avi) is the recombinant human-derived CD79B protein, expressed by HEK293 , with C-Avi, C-6*His labeled tag.

HY-P78541

	FITC-Labeled Siglec-2/CD22 Protein, Human (HEK293, Fc) CD22 molecule; CD22; Siglec-2; B-cell receptor CD22; BL-CAM; SIGLEC2; SIGLEC2FLJ22814	Human	HEK293
	The Siglec-2/CD22 protein mediates B cell interactions and may direct B cell localization within lymphoid tissues. It recognizes sialylated glycoproteins, especially α-2,6-linked sialic acid, and participates in cis-interactions at the cell surface. Siglec-2/CD22 Protein, Human (FITC, HEK293, Fc) is the recombinant human-derived Siglec-2/CD22 protein, expressed by HEK293 , with C-hFc labeled tag.

HY-P78091

	CD40 Protein, Human (Biotinylated, HEK293, His-Avi) CD40; CD40L receptor; TNFRSF5; B cell surface antigen CD40; B-cell surface antigen CD40; Bp50B cell-associated molecule; CD40 antigen; CD40 molecule, TNF receptor superfamily member 5; CD40 type II isoform; CDw40; MGC9013; nerve growth factor receptor-relat	Human	HEK293
	CD40 protein is a TNFSF5/CD40LG receptor that transduces signals through TRAF6 and MAP3K8-mediated pathways, activates ERK in macrophages and B cells, and induces immunoglobulin secretion. CD40 exists as monomers and homodimers and interacts with TRAF proteins (TRAF1, TRAF2, TRAF3, TRAF5, and TRAF6). CD40 Protein, Human (Biotinylated, HEK293, His-Avi) is the recombinant human-derived CD40 protein, expressed by HEK293 , with C-Avi, C-His labeled tag.

HY-P705095

	Siglec-2/CD22 Protein, Human (Biotinylated, HEK293, Fc) B-cell receptor CD22; BL-CAM; B-lymphocyte cell adhesion molecule; CD22 antigenMGC130020; CD22; T-cell surface antigen Leu-14	Human	HEK293

HY-P7837

	CD40 Protein, Cynomolgus (HEK293, Fc) rCynB-cell surface antigen CD40, Fc; Tumor Necrosis Factor receptor Superfamily member 5; B-cell Surface Antigen CD40; Bp50; CD40L receptor; CDw40; CD40; TNFRSF5	Cynomolgus	HEK293
	CD40 Protein, a vital TNFR superfamily member, lacks conserved residue(s) crucial for feature annotation propagation, indicating unique structural attributes. This distinctiveness may influence CD40's functional interactions within the TNFR superfamily, underscoring the need for further exploration to unravel its specific roles and regulatory mechanisms in cellular signaling pathways. CD40 Protein, Cynomolgus (HEK293, Fc) is the recombinant cynomolgus-derived CD40 protein, expressed by HEK293 , with C-hFc labeled tag.

HY-P7839

	BCMA/TNFRSF17 Protein, Cynomolgus (HEK293, Fc) rCynBCMA-Tall_bind domain-containing protein/BCMA, Fc; Tumor necrosis factor receptor superfamily member 17; B-cell maturation protein; CD269; Tnfrsf17; Bcm; Bcma	Cynomolgus	HEK293
	B Cell Maturation Antigen (BCMA) also referred to as TNFRSF17 or CD269, is a transmembrane glycoprotein member of the tumor necrosis factor receptor (TNFR) superfamily. BCMA is used as a biomarker for Multiple myeloma (MM). BCMA mainly plays an important role in B cells for their proliferation, survival and also differentiates them into plasma cells. BCMA/TNFRSF17 Protein, Cynomolgus (HEK293, Fc) is a recombinant protein with a C-Terminal Fc label, It consists of 53 amino acids (M1-A53) and is produced in HEK293 cells.

HY-P72351

	Siglec-2/CD22 Protein, Human (Biotinylated, HEK293, His-Avi) B-cell receptor CD22; BL-CAM; B-lymphocyte cell adhesion molecule; CD22 antigenMGC130020; CD22; T-cell surface antigen Leu-14	Human	HEK293
	The Siglec-2/CD22 protein mediates B cell interactions and may direct B cell localization within lymphoid tissues. It recognizes sialylated glycoproteins, especially α-2,6-linked sialic acid, and participates in cis-interactions at the cell surface. Siglec-2/CD22 Protein, Human (Biotinylated, HEK293, His-Avi) is the recombinant human-derived Siglec-2/CD22 protein, expressed by HEK293 , with C-Avi, C-6*His labeled tag.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name	Chemical Structure

HY-113134S

25-Hydroxycholesterol-d6
25-Hydroxycholesterol-d₆ (25-OHC-d₆) is the deuterium labeled 25-Hydroxycholesterol. 25-Hydroxycholesterol is a metabolite of cholesterol that is produced and secreted by macrophages in response to Toll-like receptor (TLR) activation. 25-hydroxycholesterol is a potent (EC₅₀≈65 nM) and selective suppressor of IgA production by B cells .

Cat. No.	Compare	Product Name	Application	Reactivity

HY-P80606

	CD79a Antibody (YA527) CD79A; IGA; MB1; B-cell antigen receptor complex-associated protein alpha chain; Ig-alpha; MB-1 membrane glycoprotein; Membrane-bound immunoglobulin-associated protein; Surface IgM-associated protein; CD antigen CD79a	WB, IHC-F, IHC-P, ICC/IF	Human
	CD79a Antibody is a non-conjugated and Rabbit origined monoclonal antibody about 25 kDa, targeting to CD79a. It can be used for WB,IHC-F,IHC-P,ICC/IF assays with tag free, in the background of Human.

HY-P81756

	BCMA Antibody (YA1501) TNFRSF17; BCM; BCMA; Tumor necrosis factor receptor superfamily member 17; B-cell maturation protein; CD269	FC, ELISA	Human
	BCMA Antibody (YA1501) is a rabbit-derived non-conjugated IgG antibody (Clone NO.: YA1501), targeting BCMA. BCMA Antibody (YA1501) can be used for FC, ELISA experiment in human background.

HY-P84980

	CD269/BCMA Antibody (YA4672) TNFRSF17; BCM; BCMA; Tumor necrosis factor receptor superfamily member 17; B-cell maturation protein; CD269; CD269 nanobody; BCMA nanobody	FC, ELISA	Human
	CD269/BCMA Antibody (YA4672) is a mouse-derived and non-conjugated monoclonal antibody, targeting to CD269/BCMA. It can be applicated for FC, ELISA assays, in the background of human.

HY-P85008

	CD79b Antibody (YA4700) CD79B; B29; IGB; B-cell antigen receptor complex-associated protein beta chain; B-cell-specific glycoprotein B29; Ig-beta; Immunoglobulin-associated B29 protein; CD79b; CD79b nanobody	ELISA, FC	Human
	CD79b Antibody (YA4700) is a mouse-derived and non-conjugated monoclonal antibody, targeting to CD79b. It can be applicated for ELISA, FC assays, in the background of human.

HY-P85090

	CD40 Antibody (YA4782) CD40; TNFRSF5; Tumor necrosis factor receptor superfamily member 5; B-cell surface antigen CD40; Bp50; CD40L receptor; CDw40; CD antigen CD40	ICC/IF, ELISA	Human
	CD40 Antibody (YA4782) is a mouse-derived and non-conjugated monoclonal antibody, targeting to CD40. It can be applicated for ICC/IF, ELISA assays, in the background of human.

HY-P85832

	CD40 Antibody (YA5524) CD40; TNFRSF5; Tumor necrosis factor receptor superfamily member 5; B-cell surface antigen CD40; Bp50; CD40L receptor; CDw40; CD antigen CD40	FC, ELISA	Human
	CD40 Antibody (YA5524) is a mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to CD40. It can be applicated for FC, ELISA assays, in the background of human.

HY-P81522

	CD22 Antibody (YA1267) CD22; SIGLEC2; B-cell receptor CD22; B-lymphocyte cell adhesion molecule; BL-CAM; Sialic acid-binding Ig-like lectin 2; Siglec-2; T-cell surface antigen Leu-14; CD antigen CD22	IHC-P	Human
	CD22 Antibody (YA1267) is a rabbit-derived non-conjugated IgG antibody (Clone NO.: YA1267), targeting CD22. CD22 Antibody (YA1267) can be used for IHC-P experiment in human background.

HY-P84975

	CD22 Antibody (YA4667) CD22; SIGLEC2; B-cell receptor CD22; B-lymphocyte cell adhesion molecule; BL-CAM; Sialic acid-binding Ig-like lectin 2; Siglec-2; T-cell surface antigen Leu-14; CD antigen CD22	FC, ELISA	Human
	CD22 Antibody (YA4667) is a mouse-derived and non-conjugated monoclonal antibody, targeting to CD22. It can be applicated for FC, ELISA assays, in the background of human.

HY-P85899

	CD79a Antibody (YA5591) B lymphocyte-specific MB1 protein; B-cell antigen receptor complex-associated protein alpha chain; CD 79a; CD79a; CD79a antigen; immunoglobulin-associated alpha; CD79A antigen; CD79a molecule, immunoglobulin-associated alpha; CD79A_HUMAN; Ig alpha; Ig-alpha; IGA; IgM-alpha; Immunoglobulin-associated alpha; Ly54; MB-1 membrane glycoprotein; MB1; Membrane-bound immunoglobulin-associated protein; Surface IgM-associated protein	IHC-P, WB, ICC/IF, ELISA	Human, Rat
	CD79a Antibody (YA5591) is a mouse-derived and non-conjugated IgG2b monoclonal antibody, targeting to CD79a. It can be applicated for IHC-P, WB, ICC/IF, ELISA assays, in the background of human, rat.

HY-P82250

	RanBP9 Antibody (YA1995) B cell antigen receptor Ig beta associated protein 1; BPM 90; BPM L; BPM-L; BPM90; BPML; IBAP 1; Imp 9; Importin 9; Novel centrosomal protein RanBPM; RAN binding protein 9; Ran binding protein centrosomal; Ran Binding Protein in the Microtubule organizing center; Ran binding protein M; Ran BP9; Ran-binding protein 9; Ran-binding protein M; RANB9_HUMAN; RanBP 7; RANBP 9; RanBP7; RanBP9; RanBPM.	WB, ICC/IF	Human, Mouse, Rat
	RanBP9 Antibody (YA1995) is a rabbit-derived non-conjugated IgG antibody (Clone NO.: YA1995), targeting RanBP9, with a predicted molecular weight of 78 kDa (observed band size: 91 kDa). RanBP9 Antibody (YA1995) can be used for WB, ICC/IF experiment in human, mouse, rat background.

HY-P85542

	RanBP9 Antibody (YA5234) B cell antigen receptor Ig beta associated protein 1; BPM 90; BPM L; BPM-L; BPM90; BPML; IBAP 1; Imp 9; Importin 9; Novel centrosomal protein RanBPM; RAN binding protein 9; Ran binding protein centrosomal; Ran Binding Protein in the Microtubule organizing center; Ran binding protein M; Ran BP9; Ran-binding protein 9; Ran-binding protein M; RANB9_HUMAN; RanBP 7; RANBP 9; RanBP7; RanBP9; RanBPM.	WB, ICC/IF, IP	Human
	RanBP9 Antibody (YA5234) is a mouse-derived and non-conjugated monoclonal antibody, targeting to RanBP9. It can be applicated for WB, ICC/IF, IP assays, in the background of human.